Related Experiment Video
Updated: Sep 13, 2025
Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors
Published on: September 13, 2018
Small Interfering RNAs Targeting VP4, VP3, 2B, or 3A Coding Regions of Enterovirus A71 Inhibit Viral Replication In
Yun Ji Ga1, Yun Young Go2, Jung-Yong Yeh1,3,4
1Department of Life Sciences, College of Life Sciences and Bioengineering, Incheon National University, BioComplex, Harmony-ro 265, Yeonsu-gu, Incheon 22014, Republic of Korea.
Insights
RNA interference (RNAi) using small interfering RNA (siRNA) effectively reduced Enterovirus A71 (EV-A71) viral loads and protein synthesis. This approach shows promise for developing new antiviral therapies against EV-A71 infections.
Area of Science:
- Virology
- Molecular Biology
- RNA Interference (RNAi)
Background:
- Enterovirus A71 (EV-A71) is a major cause of hand, foot, and mouth disease (HFMD) in children, associated with severe neurological complications and mortality.
- Current therapeutic options for EV-A71 infection are limited, highlighting the need for novel treatment strategies.
- RNA interference (RNAi) offers a precise mechanism for gene silencing using small interfering RNA (siRNA) to target specific RNA sequences.
Purpose of the Study:
- To design and evaluate the efficacy of various siRNAs targeting specific genomic regions of a novel EV-A71 strain.
- To assess the potential of RNAi as a therapeutic strategy against EV-A71.
Main Methods:
- Sequencing of a novel EV-A71 strain to identify siRNA target sites.
- Design of target-specific siRNAs against EV-A71 genomic regions (VP4, VP3, 2B, 3A).
- Evaluation of siRNA efficacy in EV-A71-infected HeLa cells by measuring viral titers, protein expression, cytopathic effects, and cell viability.
Main Results:
- Treatment with specific siRNAs significantly reduced EV-A71 viral titers and viral protein synthesis.
- siRNAs demonstrated protective effects by delaying cytopathic effects and enhancing cell viability in infected cells.
- No significant non-specific interferon induction was observed, and coxsackievirus B3 replication remained unaffected, indicating target specificity.
Conclusions:
- RNAi targeting EV-A71 genomic regions (VP4, VP3, 2B, 3A) is a viable strategy for controlling EV-A71 infection.
- These findings support the development of RNAi-based therapeutics for future anti-EV-A71 treatments.
Abstract:
Background: Enterovirus A71 (EV-A71) is considered as the primary causative agent of hand, foot, and mouth disease (HFMD) in young children, leading to severe neurological complications and contributing to substantial mortalities in recent HFMD outbreaks across Asia. Despite this, there is currently no effective antiviral treatment available for EV-A71. RNA interference (RNAi) is a powerful mechanism of post-transcriptional gene regulation that utilizes small interfering RNA (siRNA) to target and degrade specific RNA sequences. Objectives: The aim of this study was to design various siRNAs targeting EV-A71 genomic regions and evaluate the RNAi efficacy against a novel, previously genetically uncharacterized EV-A71 strain. Methods: A novel EV-A71 strain was first sequenced to design target-specific siRNAs. The viral titers, viral protein expression, cytopathic effects, and cell viability of EV-A71-infected HeLa cells were examined to evaluate the specific viral inhibition by the siRNAs. Results: A substantial reduction in viral titers and viral protein synthesis was observed in EV-A71-infected HeLa cells treated with specific siRNAs targeting the VP4, VP3, 2B, and 3A genes. siRNAs delayed cytopathic effects and increased cell viability of EV-A71-infected HeLa cells. Nonspecific interferon induction caused by siRNAs was not observed in this study. In contrast, replication of coxsackievirus B3, another important member of the Enterovirus genus, remained unaffected. Conclusions: Overall, the findings demonstrate that RNAi targeting genomic regions of EV-A71 VP4, VP3, 2B, or 3A could become a potential strategy for controlling EV-A71 infection, and this promising result can be integrated into future anti-EV-A71 therapy developments.
